BNP Paribas Asset Management
CLDX icon

BNP Paribas Asset Management’s Celldex Therapeutics CLDX Stock Holding History

BNP Paribas Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Sell
117,045
-5,359
-4% -$173K ﹤0.01% 932
2026
Q1 		$3.88M Sell
122,404
-761
-0.6% -$20.7K ﹤0.01% 922
2025
Q4 		$3.35M Buy
123,165
+122,496
+18,310% +$3.23M ﹤0.01% 940
2025
Q3 		$17K Buy
669
+54
+9% +$1.25K ﹤0.01% 1450
2025
Q2 		$13K Buy
+615
New +$12K ﹤0.01% 1666

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's CLDX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Celldex Therapeutics (CLDX) stake by 4.4% in Q2 2026, selling an estimated $173K and leaving 117,045 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #932.

BNP Paribas Asset Management first reported a position in CLDX in Q2 2025 and has held it in 5 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • BNP Paribas Asset Management held 117,045 shares of Celldex Therapeutics worth $4.36M as of Q2 2026.
  • BNP Paribas Asset Management sold 5,359 Celldex Therapeutics shares in Q2 2026, an estimated $173K.
  • Celldex Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #932 holding.
  • BNP Paribas Asset Management first reported a position in Celldex Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.